- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04034914
Yoga Intervention in Supporting Children With Cancer and Their Parents During Chemotherapy Infusion
July 22, 2020 updated by: Sheila Ridner, Vanderbilt-Ingram Cancer Center
A Preliminary Pilot Study to Tailor and Evaluate the Feasibility of Child and Parent Yoga (CAPY) During Chemotherapy Infusion
This trial studies how well Yoga works in supporting children with cancer and their parents during chemotherapy infusion.
Pediatric cancer and its treatment is one of life's most stressful events for children and their parents.
Yoga is an ancient holistic healing science that incorporates postures, breathing, relaxation, and meditation to facilitate harmony between body, mind, and spirit.
Participating in Yoga exercise may improve the negative psychosocial effects in children with cancer and their parents during chemotherapy treatment.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
- To determine the feasibility of Yoga for children with cancer and their parents, specifically
- Identify possible required modifications for safe and feasible practice during infusions.
- Obtain recruitment estimates and determine barriers.
- Assess satisfaction.
SECONDARY OBJECTIVES:
- To determine the feasibility of administering and acceptability of measures to assess preliminary efficacy of Yoga for the following outcomes:
- Child psychological distress (stress, anxiety).
- Parent psychological distress (stress, anxiety, anger, depression).
- Child and parent physiological stress (heart rate, respiratory rate, and blood pressure).
- Parent-child communication.
- Child physical symptoms.
OUTLINE:
Patients and parents participate in up to 8 Yoga sessions consisting of check in, awareness, breathing practices, gentle movement, and relaxation over 30 minutes each.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University School of Nursing
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 17 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children: 8-17 years of age, within 4 weeks of: 1) any new cancer diagnosis or newly diagnosed relapsed cancer, and 2) medical clearance who anticipate 3-weeks of continous contact with Monroe Carell Jr. Children's Hospital.
- Parents: 18 years of age and older, child's primary caregiver (planning to attend appointments, infusions visits, or be in hospital rooms/clinics) or secondary caregiver (an as needed back-up to primary).
Children and Parents: able to speak and understand English, absence of cognitive impairment, and willing to engage in Yoga as part of a dyad.
Exclusion Criteria:
- CHILDREN: Medical conditions that would prohibit the safe implementation of a Yoga practice
- PARENTS: Practices Yoga weekly
- PARENTS: Pregnant or plans to become pregnant during next 3 months
- CHILDREN AND PARENTS: Unwilling to work as a dyad.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Yoga Therapy
|
Ancillary studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modifications
Time Frame: Up to 2 years
|
Will be assessed qualitatively.
A tally of the specific modifications will be maintained to determine if particular modification are made more frequently than others.
|
Up to 2 years
|
|
Recruitment
Time Frame: Up to 2 years
|
The total number of eligible child-parent dyads approached to achieve an enrolled sample of 5 dyads will be tallied.
|
Up to 2 years
|
|
Retention
Time Frame: Up to 2 years
|
The number of the enrolled child-parent dyads who complete both the self-report assessments required at baseline (T1 - prior to first Yoga session), the Yoga protocol, and the measures at the end-of-infusion (T2 - prior to last Yoga session) will be tallied.
The proportion completing will be used to inform the level of over-recruitment required in future studies of efficacy.
|
Up to 2 years
|
|
Barriers
Time Frame: Up to 2 years
|
Participants who do not complete the study will be contacted and queried as to the reason for the lack of completion.
A tally of the specific barriers will be maintained to determine if particular barriers are encountered more frequently than others.
This information will inform possible modifications required to the protocol in future research.
|
Up to 2 years
|
|
Participant satisfaction
Time Frame: Up to 2 years
|
The total number of responses to the 14 satisfaction questions with a rating > 4 (maximum rating = 7) will be generated for each of the 5 parent participants.
It is expected that all participants will exceed that threshold for all questions.
If not, frequency distributions will be used to summarize the responses to each of the 14 items to assess which produced the lower ratings.
Responses to open-ended questions will be analyzed qualitatively.
Findings from both components of the satisfaction survey (program satisfaction and yoga survey) will be used to revise the Yoga protocol as needed.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Child psychological distress
Time Frame: Up to 2 years
|
Will assess child distress using Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Psychological Stress Experiences- Short Form
|
Up to 2 years
|
|
Parent psychological distress
Time Frame: Up to 2 years
|
Will assess parent distress using the PROMIS Depression - Short Form
|
Up to 2 years
|
|
Parent psychological distress
Time Frame: Up to 2 years
|
Will assess parent distress using the PROMIS Emotional Distress - Anger - Short Form
|
Up to 2 years
|
|
Parent psychological distress
Time Frame: Up to 2 years
|
Will assess parent distress using the PROMIS Anxiety
|
Up to 2 years
|
|
Child and parent physiological stress
Time Frame: Up to 2 years
|
Will assess blood pressure
|
Up to 2 years
|
|
Child and parent physiological stress
Time Frame: Up to 2 years
|
Will assess heart rate
|
Up to 2 years
|
|
Child and parent physiological stress
Time Frame: Up to 2 years
|
Will assess respiratory rate
|
Up to 2 years
|
|
Parent-child communication
Time Frame: Up to 2 years
|
Will be assessed using the Parent-Adolescent Communication Scale (PACS).
Participants answer 20-40 questions.
A total score is calculated ranging from 20-100 with higher scores indicating more positive communication.
|
Up to 2 years
|
|
Child physical symptoms
Time Frame: Up to 2 years
|
Will be assessed using the PROMIS Pediatric Physical Stress Experiences -Short Form.
|
Up to 2 years
|
|
Parent psychological distress
Time Frame: Up to 2 years
|
Parent distress will be assessed using the NIH Toolbox Perceived Stress
|
Up to 2 years
|
|
Child psychological distress
Time Frame: Up to 2 years
|
Child distress will be assessed using the PROMIS Pediatric Anxiety - Short Form
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Terrah Akard, PhD, Vanderbilt University School of Nursing
- Principal Investigator: Sheila Ridner, PhD, Vanderbilt University School of Nursing
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2019
Primary Completion (Actual)
June 29, 2020
Study Completion (Actual)
June 30, 2020
Study Registration Dates
First Submitted
July 17, 2019
First Submitted That Met QC Criteria
July 25, 2019
First Posted (Actual)
July 26, 2019
Study Record Updates
Last Update Posted (Actual)
July 24, 2020
Last Update Submitted That Met QC Criteria
July 22, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VICC SUPP 1935
- NCI-2019-04525 (Registry Identifier: NCI, Clinical Trials Reporting Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
Mayo ClinicRecruitingMalignant Abdominal Neoplasm | Malignant Pelvic Neoplasm | Childhood Malignant Solid Neoplasm | Childhood Malignant Thoracic Neoplasm | Malignant Neck Neoplasm | Metastatic Childhood Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant NeoplasmUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
Clinical Trials on Questionnaire administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
Gulseren Demir KarakilicCompletedMusculoskeletal Diseases | Chronic PainTurkey (Türkiye)
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden